NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ:SYRS). Such investors ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...

NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such investors are ...